Schechter Investment Advisors LLC Increases Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Schechter Investment Advisors LLC grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,668 shares of the company’s stock after acquiring an additional 2,884 shares during the period. Schechter Investment Advisors LLC’s holdings in Takeda Pharmaceutical were worth $1,584,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in TAK. Versant Capital Management Inc purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Takeda Pharmaceutical in the third quarter worth about $40,000. BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after buying an additional 2,596 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after buying an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Takeda Pharmaceutical in the third quarter worth about $52,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

NYSE:TAK opened at $14.84 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $47.22 billion, a P/E ratio of 37.10, a P/E/G ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The business’s 50-day moving average is $13.44 and its 200 day moving average is $13.89.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.